Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Bitte wählen Sie die Menge aus.
CAS RN: 129-06-6 | Produkte #: W0005
Warfarin Sodium (contains Isopropyl Alcohol)
×
![]()
×
Reinheit: >98.0%(HPLC)
Synonyme
- 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)
Produktdokumente:
| Einheit | Stückpreis | Belgien | Japan* | Menge |
|---|---|---|---|---|
| 5G |
€36.00
|
2 | ≥60 |
|
| 25G |
€135.00
|
12 | ≥40 |
|
*In Belgien verfügbare Lagerbestände werden in 1 bis 3 Tagen geliefert.
*In Japan verfügbare Lagerbestände werden in 1 bis 2 Wochen geliefert. (unter Ausschluss von regulierten Artikeln und Trockeneislieferungen).
| Artikel # | W0005 |
| Reinheit / Analysenmethode | >98.0%(HPLC) |
| Summenformel / Molekülmasse | C__1__9H__1__5NaO__4 = 330.31 |
| Physikalischer Zustand (20 °C) | Solid |
| Lagerungstemperatur | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Unter Inertgas lagern | Store under inert gas |
| Zu vermeidende Bedingungen | Air Sensitive |
| CAS RN | 129-06-6 |
| Verwandte CAS RN | 81-81-2 |
| Reaxys Registrierungsnummer | 5469050 |
| PubChem-Stoff-ID | 87560363 |
| Merck-Index (14) | 10038 |
| MDL-Nummer | MFCD00083223 |
Spezifikation
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 91.0 % |
| 2-Propanol | 7.0 to 9.0 % |
Eigenschaften
| Löslichkeit (wenig löslich in) | Ether, Chloroform |
GHS
| Piktogramm |
|
| Signalwort | Gefahr |
| Gefahrenhinweise | H300 : Lebensgefahr bei Verschlucken. H360 : Kann die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. H370 : Schädigt die Organe. H372 : Schädigt die Organe bei längerer oder wiederholter Exposition. H373 : Kann die Organe schädigen bei längerer oder wiederholter Exposition. H412 : Schädlich für Wasserorganismen, mit langfristiger Wirkung. |
| Sicherheitshinweise | P260 : Staub nicht einatmen. P201 : Vor Gebrauch besondere Anweisungen einholen. P264 : Nach Gebrauch Haut gründlich waschen. P280 : Schutzhandschuhe/ Schutzkleidung/ Augenschutz/ Gesichtsschutz/ Gehörschutz Tragen. P308 + P311 : BEI Exposition oder falls betroffen: GIFTINFORMATIONSZENTRUM/Arzt anrufen. P301 + P310 + P330 : BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt anrufen. Mund ausspülen. |
Verwandte Gesetze:
| EC-Nummern | 204-929-4 |
| RTECS # | GN4725000 |
Transportinformationen:
| UN-Nummer | UN1544 |
| Klasse | 6.1 |
| Verpackungsgruppe (DOT-AIR) | II |
| HS-Nr. (Import / Export) (TCI-E) | 2932209090 |
Anwendung
Warfarin Sodium (contains Isopropyl Alcohol) Binding of Warfarin to Human Serum Albumin
Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes.
【SPR】
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
＜Assay condition＞
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.
＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.
＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
【Method using fluorescent probes】
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
＜Assay condition＞
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
In these ways, our warfarin can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.
References
- Fluorescent Dye Cocktail for Multiplex Drug￢Site Mapping on Human Serum Albumin
- High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE
- Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels
- Characterizing a drug's primary binding site on albumin
- Structural basis of the drug-binding specificity of human serum albumin
Anwendung
Reviews of Pharmacology of Warfarin
References
- Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol
- Systematic overview of warfarin and its drug and food interactions
- Pharmacogenetics of warfarin elimination and its clinical implications
- Pharmacogenetics of warfarin: current status and future challenges
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
PubMed Literatur
Artikel / Broschüren
Produktdokumente (Hinweis: Für einige Produkte sind keine Analysediagramme verfügbar.)
Sicherheitsdatenblatt (SDB)
Bitte wählen Sie Sprache.
Das angeforderte SDB ist nicht verfügbar.
Bitte Kontaktieren Sie uns für mehr Informationen.
Spezifikationsdokumenten
AZ & andere Zertifikate
Bitte geben Sie die Lotnummer ein
Falsche Chargennummer wurde eingegeben. Bitte geben Sie nur 4-5 alphanumerische Zeichen vor dem Bindestrich ein.
Muster-AZ
Dies ist ein Muster-AZ und repräsentiert möglicherweise nicht eine kürzlich hergestellte Charge des Produkts.
Ein Muster-AZ für dieses Produkt ist zur Zeit nicht verfügbar.
Analytische Diagramme
Bitte geben Sie die Lotnummer ein
Falsche Chargennummer wurde eingegeben. Bitte geben Sie nur 4-5 alphanumerische Zeichen vor dem Bindestrich ein.
Das angeforderte Analysediagramm ist nicht verfügbar. Wir entschuldigen uns für die Unannehmlichkeiten.